Boothbay Fund Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Boothbay Fund Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,200	Closed	-$772K	–	2004
2021 Q2	$772K	Buy	11,200 +11,088	+9,900%	+$846K	0.02%	808
2021 Q1	$863K	Buy	+112	New	+$10.3K	0.03%	676
2020 Q2	–	Sell	-35	Closed	-$686K	–	1021
2020 Q1	$686K	Buy	+35	New	+$7.53K	0.06%	388
2019 Q2	–	Sell	-735	Closed	-$8.66M	–	792
2019 Q1	$8.66M	Buy	+735	New	+$74.1K	0.84%	14

Other funds holding LKFT

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's LKFT Position: Q3 2025 in Review

Boothbay Fund Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2025, closing a stake of 21,866 shares — an estimated $612K sold.

Boothbay Fund Management first reported a position in LKFT in Q1 2021 and held it in 7 quarters. The position peaked at $1.9M in Q1 2021. 92 funds tracked by Wall St. Rank hold LKFT as of Q3 2025.

Boothbay Fund Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2025 after selling out during the quarter.
Boothbay Fund Management sold 21,866 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2025, an estimated $612K.
Boothbay Fund Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 7 quarters.
Boothbay Fund Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $1.9M in Q1 2021.
92 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.